Stock Market Today: Dow Higher As S&P 500 Scores Record; Nvidia Clears Key Level (Live Coverage)

U.S. stocks closed higher with the S&P 500 hitting a record as AI-related names helped drive gains; Nvidia climbed while ServiceNow fell after announcing a planned $7.75 billion acquisition of a startup. Investors largely shrugged off a stronger-than-expected GDP print that reduced the odds of a January Fed rate cut, leaving markets to focus on tech-led momentum and positioning ahead of further economic and policy signals.

Analysis

Market structure: The immediate winners are AI infrastructure and semiconductor suppliers (NVDA and upstream partners) and select specialty healthcare plays (NVO after FDA news); losers include high‑multiple enterprise software where M&A/dilution risk is elevated (NOW). A stronger‑than‑expected GDP that trims January cut odds pushes real yields up, compressing long‑duration tech multiples and re‑pricing growth vs cyclical exposure over the next 1–6 months. Expect upward pressure on GPU prices/allocations and cloud capex for 6–18 months, tightening supply of leading wafers and driving pricing power for dominant OEMs.

Risk assessment: Tail risks include a sticky Fed regime (no cut until H2 2025), an AI regulatory crackdown, or a sudden GPU supply relief that collapses pricing — each could swing returns ±30–50% for individual names. Time horizons split: days for momentum/IV spikes, 1–3 months for macro/reaction to Fed signals and M&A headlines, and 6–24 months for structural AI adoption. Hidden dependencies: TSMC/ASML capacity, enterprise cloud spend cadence, and NOW integration/dilution mechanics are second‑order drivers.

Trade implications: Favored direct plays are a 2–4% portfolio long in NVDA (target +25–40% in 6–12 months) executed via 6–12 month call spreads to cap cost, and a 1–2% opportunistic long in NVO (target +15–25% in 3–9 months). Short or buy protective put spreads on NOW (size 1–2%) to capture M&A risk; reduce core bond duration by 25–50% and rotate +200 bps into semis/AI-exposed large caps. Hedge international equity FX exposure (USD hedges) if extending global positions.

Contrarian angles: The market may be understating valuation sensitivity if rate cuts are delayed — NVDA upside is real but clustered and volatile; conversely NOW could be oversold if the deal is strategically value‑accretive and integration succeeds, offering a rebound in 3–9 months. Historical parallels: prior tech re‑rating cycles show heavy short‑term dispersion followed by concentration in a few platform winners; watch for volume/flow divergences as a reversal signal. Unintended consequence: sticky rates could slow broader software adoption, capping multiples across tech even as AI spend rises.

Key Decisions for Investors

• Establish a 2–4% portfolio long position in NVDA via a 9–12 month call spread (debit spread) to target +25–40% upside while limiting premium; scale in on pullbacks of 8–12% and trim on 25–30% gains.
• Initiate a 1–2% hedge/short on NOW using a 3–6 month put spread to capture acquisition/dilution risk; cover or unwind if NOW’s forward revenue guidance or deal financing detail materially improves within 90 days.
• Allocate a 1–2% position to NVO (equities or 6–9 month calls) to play FDA approval momentum; target +15–25% within 3–9 months and take profits into any 15% rally.
• Reduce core fixed‑income duration exposure by 25–50% (sell 7–10yr equivalents) and redeploy ~200 bps of portfolio weight into AI/semiconductor large caps; concurrently hedge international equity FX exposure with short USD‑hedged forwards if holding non‑USD names.